When Do Allergy Shots Start Working? Your Early Signs Self-Monitoring Guide

The earliest patient-detectable signs that allergy shots are working typically appear between 3 and 6 months into treatment and include: needing fewer rescue antihistamine doses per week without symptom rebound, sleeping through the night without waking due to nasal congestion for the first time in months, tolerating an allergen exposure that previously triggered significant symptoms (such as visiting a friend with a cat or walking through a park during pollen season with milder symptoms than expected), reduced eye itching and rubbing frequency, shorter duration of acute flares when they do occur, and less severe asthma symptoms if allergy-triggered asthma is part of your picture. Track these signals weekly in a simple symptom diary to detect the gradual changes that are easy to miss without a systematic record to compare against.

Distinguishing genuine immunotherapy benefit from seasonal variation requires systematic tracking. Allergy shots produce true improvement — one key signal is improvement that holds across multiple days, weeks, and environments, not just a random good day. Track your symptom severity on a 0-to-10 scale daily. After 3 to 6 months, compare your average weekly scores to your pre-treatment baseline from the same season in previous years. Genuine improvement typically shows as lower average scores during your peak allergen season, less day-to-day variability, and reduced reliance on rescue medications. The 30 to 40 percent placebo response documented in allergy trials (Nelson, JACI 2007) means early improvement that fluctuates dramatically is less reliable than sustained consistent improvement tracked over months.

Yes — the AAAAI recommends symptom diary tracking as a standard tool for detecting gradual allergy shot improvement. Patients often fail to notice incremental improvement because the change is slow and their memory anchors on recent days rather than the baseline from treatment start. A simple weekly diary recording your worst symptom day score, number of rescue antihistamine uses, and sleep quality score gives you objective data to compare against. After 6 months, you should be able to look back at your baseline week-1 entries and see a trend, even if day-to-day it feels unchanged. Without a written record, patients frequently underestimate their true improvement or overestimate it — both errors lead to poor treatment decisions.

Some temporary worsening during early build-up is documented and considered normal. Local injection site reactions — redness, swelling, and itching at the injection site — occur in 26 to 86 percent of patients and can be uncomfortable for hours after an injection. A transient mild rise in allergen-specific IgE occurs in early treatment before it eventually declines, which may temporarily heighten sensitivity in some patients. Mild fatigue following injections is also common. These experiences should be reported to your allergist but are not signals to stop treatment. The AAAAI/ACAAI Practice Parameter recommends continuing concurrent antihistamines or nasal corticosteroids during build-up to bridge the symptom gap while the immune system is priming.

Nine months without improvement warrants a careful clinical evaluation but not automatic discontinuation. First, determine whether 9 months refers to 9 months from the first injection or 9 months from reaching full maintenance dose — these can differ significantly if build-up was slow or required dose reductions due to missed appointments. The AAAAI/ACAAI Practice Parameter recommends non-responder evaluation at 12 months of maintenance dosing. Key assessment points include: whether the target maintenance dose was actually achieved, whether allergen formulation accurately covers your most significant IgE sensitivities, whether attendance gaps caused dose reductions that reset your immune priming, and whether concurrent medications are masking improvement. Formal evaluation typically involves reviewing injection logs, dose levels, and potentially repeating specific IgE testing or skin testing to verify the formulation.

Yes, this is a clinically recognized challenge. Concurrent antihistamines and nasal corticosteroids are recommended during allergy shot build-up to manage symptoms while immunotherapy takes effect. The trade-off is that effective concurrent medications can suppress your awareness of whether allergy shots are providing independent benefit. Some allergists suggest a supervised medication-reduction trial after 6 to 12 months to reveal underlying improvement. However, do not discontinue concurrent medications without discussing this with your allergist first — stopping nasal corticosteroids abruptly can cause symptom rebound that is difficult to interpret. The structured approach involves gradually tapering one medication at a time while monitoring symptoms carefully over several weeks.